China Pharma Financials

Trends View

Profitability View

Liquidity View

Fundamentals View

Competition View

China Pharma Stock Summary

China Pharma competes with Catalent, Amphastar, ANI Pharmaceuticals, Alkermes Plc, and Dr Reddys. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the Peoples Republic of China. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the Peoples Republic of China. China Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 236 people.

China Pharma Key Financial Ratios

China Pharma Key Balance Sheet Accounts

China Pharma Key Income Statement Accounts

China Pharma Key Cash Accounts

China Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining China Pharma's current stock value. Our valuation model uses many indicators to compare China Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across China Pharma competition to find correlations between indicators driving China Pharma's intrinsic value. More Info.China Pharma Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, China Pharma's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Pharma's earnings, one of the primary drivers of an investment's value.

China Pharma Holdings Systematic Risk

Today, most investors in China Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various China Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of China Pharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of China Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of China Pharma Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of China Pharma Holdings based on widely used predictive technical indicators. In general, we focus on analyzing China Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build China Pharma's daily price indicators and compare them against related drivers.

When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.